Elsevier and Norway Agree on New Open-Access Deal

Under a two-year pilot agreement, articles published by Norwegian academics will be free to read in almost all of the publisher’s journals.

Written byDiana Kwon
| 2 min read
norway university of oslo elsevier publishing publish-and-read unit open access

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: The University of Oslo is part of the agreement.
© ISTOCK.COM, FONT83

After unsuccessful negotiations between a coalition of Norwegian organizations and the academic publisher Elsevier culminated in cancelled subscriptions earlier this year, the two have successfully established a new nationwide licensing agreement. The deal, which was announced yesterday (April 23), is a pilot program that covers a period of two years, during which articles with corresponding authors from Norway will be published open access in most of Elsevier’s journals.

“We are very happy about this,” says Nina Karlstrøm, the leader of the negotiation team for the Norwegian Directorate for ICT and Joint Services in Higher Education and Research (Unit), which represents seven universities and 39 research institutions in Norway. “As far as I know, we are the first to have one of these deals” with Elsevier.

Consortia in other countries in Europe, such as Sweden, Germany, and Hungary, have ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Diana is a freelance science journalist who covers the life sciences, health, and academic life. She’s a regular contributor to The Scientist and her work has appeared in several other publications, including Scientific American, Knowable, and Quanta. Diana was a former intern at The Scientist and she holds a master’s degree in neuroscience from McGill University. She’s currently based in Berlin, Germany.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies